Encompass Health (NYSE: EHC) EVP receives 19,874-share stock awards

Rhea-AI Filing Summary

Encompass Health Corp executive John Patrick Darby, EVP, General Counsel & Secretary, reported two stock awards. On February 18, 2026, he acquired 17,720 shares of common stock, and on February 19, 2026, he received 2,154 restricted shares. Following these grants, he directly holds 99,584 shares of Encompass Health common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Darby John Patrick

(Last) (First) (Middle)

9001 LIBERTY PARKWAY

(Street)

BIRMINGHAM AL 35242

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Gen Counsel & Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Encompass Health Common Stock	02/18/2026		A		17,720(1)	A	$0	97,430	D
Encompass Health Common Stock	02/19/2026		A		2,154(2)	A	$0	99,584	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This issuance of restricted stock is the result of the satisfaction of performance criteria set out in the terms of a performance share unit award made on February 23, 2023.

2. Annual award of restricted stock pursuant to the Corporation's 2025 Omnibus Performance Incentive Plan.

	Patrick Darby	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Encompass Health (EHC) report for John Patrick Darby?

Encompass Health executive John Patrick Darby reported two stock awards totaling 19,874 shares. He received 17,720 shares on February 18, 2026, and 2,154 restricted shares on February 19, 2026, increasing his direct ownership to 99,584 common shares.

Were the recent Encompass Health (EHC) Form 4 transactions open-market purchases or stock awards?

The transactions were stock awards, not open-market purchases. Both entries use code “A” for grants, with a price of $0.00 per share, reflecting equity compensation rather than cash purchases, according to the Form 4 details and accompanying footnotes.

How many Encompass Health (EHC) shares does John Patrick Darby own after these awards?

After the most recent award, John Patrick Darby directly owns 99,584 shares of Encompass Health common stock. This figure reflects his holdings following the February 19, 2026 grant of 2,154 restricted shares reported in the Form 4 filing.

What do the Form 4 footnotes reveal about the Encompass Health (EHC) stock awards?

The footnotes state that 2,154 restricted shares were issued after performance criteria were satisfied under a February 23, 2023 performance share unit award, and 17,720 shares represent an annual restricted stock award under Encompass Health’s 2025 Omnibus Performance Incentive Plan.

What is transaction code “A” in the Encompass Health (EHC) Form 4 for John Patrick Darby?

Transaction code “A” in this Form 4 indicates a grant, award, or other acquisition of stock. In Darby’s case, both entries represent restricted stock and performance-based share awards provided as part of his compensation, at no cash cost per share.